Course Category: Medical

The latest advantages of utilizing 3D printing for the fabrication of microfluidic devices and organ-on-a-chip systems have opened up new horizons in biomedical research and personalized medicine. 3D printing offers precision and flexibility that traditional methods often cannot achieve, enabling the rapid and cost-effective production of intricate microscale structures that mimic the complexity of human organs and tissue environments. Researchers can now customize microfluidic devices to emulate specific physiological conditions, allowing for more accurate drug testing and disease modeling. Moreover, the ability to integrate multiple materials in a single print enables the recreation of tissue interfaces and vascular networks, fostering the development of more lifelike organ-on-a-chip platforms. This innovative approach promises to revolutionize drug development, toxicology testing, and disease understanding, offering a glimpse into a future where personalized medicine is driven by these advanced, 3D-printed microsystems.

Speaker:

Elliot McAllister

Elliot McAllister is the Founder of Skyphos, the first 3D printing fabrication system enabling a shift from the enterprise of mold-based prototyping and production for healthcare-based needs. Mr. McAllister has experience and expertise in Materials Science, Mechanical Engineering, Optics and developing microfluidic platforms. He has an advanced degree from Virginia Tech where his research focused on micro-3D printing 4 different forms of solid matter. Based on additive manufacturing technology, Mr. McAllister launched Skyphos to eliminate the barriers to entry of new applications in medical diagnostics and focuses on micro-scale requirements of microfluidics (uF), Lab-on-a-Chip (LOAC), Point-of-Care (POC) devices, as well as the needs of the sensors community. Skyphos leverages robotics, specialized materials, and the innate flexibility of a Digital Manufacturing platform to enable start-ups to get to market sooner – and large companies to reduce costs associated with developing new ones.

Natan Barros

I am a dedicated researcher with a passion for academic and translational research. My journey began with a bachelor’s degree in chemistry, where I developed a keen interest in biochemistry and polymers. Pursuing advanced studies in biotechnology at Sao Paulo State University (UNESP), one of Brazil’s leading institutions, I delved into biomaterials science and tissue engineering during my master’s and Ph.D. There, I focused on developing functional biomaterials for drug delivery and chronic wound healing. In 2019, I embarked on a transformative experience as a visiting researcher at the University of California, Los Angeles (UCLA) under the guidance of Dr. Ali Khademhosseini. At UCLA, I pioneered a microfluidic in vitro platform to model skin and explored innovative areas such as 3D bioprinting of functional skeletal muscle tissues and localized melanoma treatment. My dedication to groundbreaking research continued at the Terasaki Institute for Biomedical Innovation (TIBI), where I collaborated with esteemed mentors like Dr. Khademhosseini and Dr. HanJun Kim. Together, we investigated cutting-edge projects funded by NIH, including drug-eluting biomaterials for chemoembolization and bioengineered solutions for enterocutaneous fistula healing. Now, as a faculty fellow, I lead my research group at TIBI, focusing on shear-thinning hydrogels, microfluidic droplet platforms, and 3D bioprinted in vitro tissues.

Soon Seng Ng

Dr. Soon Seng Ng is an accomplished biomedical scientist and Director of Biology at Systemic Bio, leading groundbreaking research in 3D bioprinting and MPS development. With prior roles at Sana Biotechnology, Imperial College London, and Stanford University, Dr. Ng has made significant contributions in liver stem cell biology, disease modeling, drug discovery, and liver cell therapy. He has over 20 peer-reviewed publications, and his work has garnered awards and multi-million dollars grants, highlighting his impact on translational medicine and his commitment to bringing new therapies to patients. Dr. Ng’s dedication to advancing biomedical research and improving patient outcomes establishes him as a highly influential figure in the field.

Anna Bickham

Anna Bickham is the cofounder and CEO of Acrea 3D. Anna received her Ph.D. in chemistry from Brigham Young University in Dr. Adam Woolley’s lab, focusing on traditional and 3D printed fabrication of various medical and electrical microfluidic devices. She then spun Acrea 3D out of the technology used during her doctoral program, originating out of Dr. Greg Nordin’s lab. Acrea 3D specializes in micro-scale DLP-SLA printing of void features down to 20 um. By leveraging mechanical, software, and physical techniques, Acrea 3D enables true microfluidic 3D printing.

Register (Free)

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Biomaterial development plays a crucial role in advancing the 3D printing industry, particularly in the fields of healthcare, regenerative medicine, and tissue engineering. The ability to create complex, patient-specific structures using 3D printing and bioprinting opens up unprecedented possibilities for personalized medical treatments and advancements in healthcare. Biomaterials specifically designed for 3D printing (or Bioinks for Bioprinting) enable the fabrication of intricate, biocompatible structures with precise mechanical and biological properties. By tailoring biomaterial formulations to mimic the characteristics of native tissues, researchers and clinicians can create scaffolds, implants, and organ constructs that promote cell growth, tissue regeneration, and integration with the host body. Moreover, the continuous exploration and refinement of biomaterials for 3D printing contribute to the development of innovative medical devices, drug delivery systems, and surgical tools. As biomaterial development progresses, it drives the expansion of the 3D printing industry’s capabilities, offering new solutions for personalized healthcare and revolutionizing patient care and treatment outcomes. In this upcoming event, we invite a panel of experts to dive deep into the current status, immediate future, and long-term outlook on biomaterials/bioink for healthcare 3D printing applications.

Speakers:

Julien Barthes

Dr. Julien BARTHES, CEO and co-founder of 3Deus Dynamics holds an engineering degree in physical chemistry of polymers and a PhD in biomaterials science. He has a solid experience in tissue engineering and additive manufacturing He experienced project leading of different type of funding and domains, as PANBIORA-H2020 and IMMODGEL-FP7 (European projects on biomaterials/implants) or FASSIL (National FUI project on AM). During these projects he maturated a strong experience in the field of tissue engineering, with a deep focus on cell and biomaterials interaction, as well as in AM technologies. He was involved in both academic and industrial R&D projects with a constant implication in the scientific dissemination, with more than 25 articles published. Before starting 3Deus Dynamics in 2020, he was working for the past 6 years in a MedTech startup developing ENT medical devices and he managed the development of medical devices from the laboratory stage to their marketing.

Gurkaran Chowdhry

Gurkaran Chowdhry is a polymer physicist and a co-founder of 3D BioFibR Inc, a pioneering biotechnology company at the forefront of biomaterial innovation and manufacturing. As the Director of Business Development and Operations, he has raised $5 million in funding within three years, enabling the successful commercialization of five groundbreaking biomaterial products through direct sales and strategic partnerships. As an innovative leader, Gurkaran is determined to bring 3D BioFibR to the forefront of biomaterial fabrication and help move 3D bioprinting technologies towards clinical applications.

Rao S. Bezwada 

An accomplished scientist and entrepreneur, Rao S. Bezwada, Ph.D. established Bezwada Biomedical, an innovation-based and technology-driven research company, in 2003. The company is focused on developing a wide range of novel absorbable polymeric biomaterials to enhance quality of life by producing next generation bioabsorbable medical devices with therapeutic applications. Dr. Bezwada earned a doctorate in chemistry from the Stevens Institute of Technology in New Jersey and has over 40 years of research experience in the medical device industry, including 20 years of service at Ethicon, Inc. (a Johnson & Johnson Company). While at Ethicon, Dr. Bezwada’s research and development efforts led to the launch of a number of products, including Monocryl®, a new ultra-pliable synthetic absorbable monofilament suture. This product has represented worldwide sales of more than two (2) billion dollars since its launch in 1993 and current annual sales of over 100 million dollars. In recognition of this invention, along with its development, Johnson & Johnson, Inc. awarded Dr. Bezwada the prestigious Johnson Medal in 1996. Dr. Bezwada has been a prolific inventor and has been issued more than 135 U.S. patents on absorbable polyurethanes, absorbable amino acid polymers, absorbable polyester amides, absorbable polyoxaesters, and controlled release polymers. FDA-approved products such as MONTAGE® Putty, MONTAGE Fast Set Putty, Montage Flowable Putty, and PERMATAGE Putty, marketed by Abyrx for wound healing and bone applications, are based on Bezwada Biomedical’s absorbable polyurethane technology. Dr. Bezwada has also pioneered specialty bio-inks for 3D printing applications. In addition to his passion for science and technical accomplishments, Dr. Bezwada has also established a non-profit organization, Society for Basic Needs, in India. This organization has a mission aimed at improving the quality of life for those less fortunate by providing them with essential amenities and opportunities for health and education.

Neeti Srivastava

Neeti Srivastava is the Director, R&D, Business Development and Quality Affairs at Bezwada Biomedical. Dr. Srivastava has 14 years of experience in development of absorbable polymers for medical devices, drug delivery and 3D Bioprinting. She made contributions for the development of absorbable polyurethane formulation that received 510K approval from the FDA and was commercialized as a bone hemostat by Abyrx, Inc. She led the quality efforts resulting in ISO 9001 certification of Bezwada Biomedical. Furthermore, Dr. Srivastava has authored several scholarly articles and has been published in international scientific journals, along with presentations at American Chemical Society and Society for Biomaterials conferences.

Nicole Black

Dr. Nicole Black is the Vice President of Biomaterials and Innovation for Desktop Health. Nicole grew up in Michigan before moving to Boston to attend Boston University as Trustee Scholar. There, she studied Biomedical Engineering with a minor in Mechanical Engineering and a concentration in Nanotechnology. Following graduation, Nicole worked briefly at a startup company developing drug-eluting implants for the treatment of epilepsy. In 2014, Nicole started her PhD work at Harvard University in the lab of Professor Jennifer Lewis. During graduate school, Nicole worked on interdisciplinary projects between the Wyss Institute for Biologically Inspired Engineering and Mass Eye and Ear hospital, alongside Dr. Aaron Remenschneider and Dr. Elliott Kozin. Specifically, she focused on developing biomimetic eardrum grafts using novel materials and 3D printing technologies. Nicole graduated with her PhD in 2020 and started a postdoctoral fellowship as a Gliklich Healthcare Innovation Scholar. During this time, Nicole co-founded Beacon Bio, a startup company developing 3D-printed regenerative tissue grafts. Beacon Bio was named the runner-up prize winner in the MassMEDIC IGNITE pitch competition and a $25k prize winner in the Harvard i-Lab President’s Innovation Challenge. As the CEO, Nicole led an early-stage acquisition of Beacon Bio to Desktop Metal in 2021. Nicole currently leads a team at Desktop Health, a healthcare division of Desktop Metal, to bring the PhonoGraft device for eardrum perforation repair to patients. She is also leading partnerships with other medtech companies to help them realize the potential of the 3D-Bioplotter for innovative medical devices. Nicole’s accolades include the Collegiate Inventors Competition Graduate Team Winner (2018), the Baxter Young Investigator Award (2020), the Lemelson-MIT Student Prize (2021), and Forbes 30 Under 30 in Manufacturing and Industry (2022). Nicole is passionate about inspiring the next generation of scientists and engineers, and she has led a variety of outreach and mentoring programs for K-12 and undergraduate students. In her free time, Nicole enjoys crafting, reading, kayaking, and spending time with her cat, Merlin.

Moderator:

Craig Rosenblum

Craig Rosenblum (TWITTER: @RosenblumCraig) is the Vice President & General Manager of Himed. Over 30 years of operation, Himed has become a global leader in calcium phosphate based biomaterial production and has developed proprietary plasma spray coatings and surface treatments. Craig and his team collaborate directly with dental and medical device manufacturers around the world to provide innovative biomaterial solutions. Craig discovered a unique application for MATRIX MCD® post-processing additively manufactured titanium implantable devices using Himed’s proprietary and biocompatible resorbable blast media. Himed has since formed a strategic partnership with Lithoz, a global market leader in 3D printing, to develop new bioceramic bioinks for medical 3D printing. Craig received his B.S. and M.S. degree in Materials Science & Engineering with a Biomaterials concentration from The Johns Hopkins University (Baltimore, MD). With a focus in biomaterials characterization, his groundbreaking research explored the variations in the microstructure and mechanical properties of dental enamel. These studies were the first to demonstrate the unique heterogeneous nature of enamel. Craig currently serves on The Johns Hopkins University Materials Science & Engineering Advisory Board.

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Are you ready to revolutionize healthcare from the comfort of your screen? We’re thrilled to invite you to an exceptional virtual event that’s set to reshape the way we think about Point of Care Additive Manufacturing! In this upcoming virtual event, we will not only continue to highlight 3D printing applications but also will broaden our perspectives on how it can be seamlessly integrated into existing healthcare systems and other 3D technologies like AR/VR, and virtual surgical planning. The invited speakers are from three different continents, bringing us insights, experiences, and inspirations with their unique lenses to the 3D world. 

Speakers:

Erik Boelen

After his masters in biomedical engineering and his PhD in biomaterials, Erik started his career in medical 3D printing as Product Specialist for Mimics (medical image processing software) at Materialise in 2007. In 2010 he spent one year in Kuala Lumpur, Malaysia for Materialise to build the sales and support team for APAC. Back in Materialise Headquarters in Belgium, he assumed the role of Marketing Manager for the Mimics Innovation Suite. In 2012, Erik joined the startup Xilloc as its Chief Operations Officer. Xilloc designs and manufactures custom-made medical devices and was a pioneer in using 3D printing for implants (we made the world’s first complete 3D printed titanium mandible). In his role as COO, Erik was mainly responsible for sales, marketing and quality management and he built a QMS for ISO 13485 from scratch and got it certified. After nearly a decade, in 2021 he decided to take the plunge and start his own company QasE3D (pronounced as Case-three-dee) as a consultant for Quality Management and 3D printing. He currently helps medical device companies and PoC facilities to implement a digital QMS for ISO 13485 and acts as an agent for several companies with innovative 3D technology to help surgeons.

Jay Banerjee

Jay is the co-founder and President of ImmersiveTouch, a pioneer in augmented reality clinical intelligence & surgical navigation software. Jay is responsible for running all facets of the business and has a proven executive management track record driving growth and innovation in healthcare. He is a advocate for improving patient care and enhancing physician capabilities, an accomplished speaker, and a contributor to publications such as Forbes and Business Insider. He recently completed a certification in Economics of Blockchain and Digital Assets from The Wharton school. Prior to joining ImmersiveTouch in 2014, Jay was a project manager at JPMorgan Chase and Co. and a business consultant at Illinois Business Consulting. Jay holds a BS in Industrial Engineering, Finance, and Economics from the University of Illinois at Urbana-Champaign and an MA in Consciousness and Human Potential from Maharishi International University.

Shannon Walters

Shannon Walters navigates this world with a passion to seek practical applications of knowledge and technology. As Executive Technical Director at the 3D Quantitative and Imaging Laboratory he leads a team approaching 40 people to apply this passion in the medical image processing realm. With an educational background in Radiology Management and Information Systems, he routinely seeks synergies that link the needs of clinicians/radiologist to the capabilities of technologists. With more than 17 years of experience dedicated to 3D Imaging, Shannon has a unique perspective regarding 3D Imaging software and 3D Printing.

Rodrigo Salazar-Gamarra

Prof. Dr. Rodrigo Salazar-Gamarra DDS, MSc, Ph.D. Is CEO of M3D, and a technological innovation consultant for healthcare, awarded by the MIT Technology Review as “Humanitarian Innovator 2018 for Latin America” for his actions as director and researcher of the “Plus Identity Institute (+ID)” in Brazil. Associate researcher at the “Renato Archer TI Center (CTI)”, from the Ministry of Science & Innovation of Brazil. Professor at the Postgraduation School of the “Universidad Peruana Cayetano Heredia (UPCH)” , Maxillofacial Prosthodontics professor at the “Universidad Cientifica del Sur(UCSUR)”, and Digital dentistry teacher at the “Universidad Peruana de Ciencias Aplicadas(UPC)” in Perú. Volunteer at the Digital Digital Transformation Laboratory of the Digital Government Secretariat of the Presidency of the Council of Ministers (PCM) of Peru. Former IAA President, VP of the Latin American Society of Maxillofacial Prosthodontics, and member of the Digital Dentistry Society.

Chris LeCastillo

Chris LeCastillo is the Innovations Manager for the Stanford 3D and Quantitative Imaging Laboratory, helping lead a team of nearly 40 under Shannon’s directorship. His extensive background in IT, 10 years in the medical field as a Radiologic Technologist, and education in Imaging Informatics and Health Leadership help him drive forward meaningful innovations in the 3DQ Lab like 3D Printing and Clinical AI. Chris also manages the XR Neurosurgical Navigation program at Stanford.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

3D printing technology has brought significant advancements in the field of Orthotics and Prosthetics. Here are some ways in which 3D printing can benefit Orthotics and Prosthetics: 1) Customization: 3D printing enables the creation of custom orthotics and prosthetics that are tailored to the unique needs of individual patients. This ensures a better fit and comfort level, leading to improved patient outcomes. 2) Reduced Lead Times: Traditional orthotics and prosthetics production methods can be time-consuming and require multiple appointments. With 3D printing, the time from design to production can be significantly reduced, allowing patients to receive their devices more quickly. 3) Cost Savings: 3D printing can reduce costs associated with traditional manufacturing methods, as it eliminates the need for expensive molds or tooling. Additionally, the ability to create custom devices means that there is less waste and fewer materials required. 4) Improved Design Capabilities: 3D printing allows for intricate designs and complex geometries that are difficult or impossible to achieve with traditional methods. This can lead to improved functionality and aesthetics of orthotics and prosthetics. 5) Iterative Prototyping: 3D printing enables orthotists and prosthetists to quickly iterate and improve upon designs, allowing for rapid development and testing of new products. Overall, 3D printing has the potential to significantly improve the quality of life for patients in need of orthotics and prosthetics by providing customized, cost-effective, and efficient solutions. In this highly anticipated event for entrepreneurs, scientists, industrialists, and providers in the space, we want to invite you to join a stimulating conversation on the current status and future outlook of 3D printing in orthotics and prosthetics.

Speakers:

Aadeel Akhtar

Dr. Aadeel Akhtar is the CEO and Founder of PSYONIC, a company developing advanced bionic limbs that are accessible to all people with limb differences. PSYONIC’s Ability Hand is an FDA-registered bionic hand that is the fastest on the market, robust to impacts, and the first to give users touch feedback. It is also covered by Medicare in the US. The Ability Hand is being used by patients and researchers globally, including Meta and NASA. Dr. Akhtar received his Ph.D. in Neuroscience and M.S. in Electrical & Computer Engineering from the University of Illinois at Urbana-Champaign in 2016. He received a B.S. in Biology in 2007 and M.S. in Computer Science in 2008 at Loyola University Chicago. His research is on motor control and sensory feedback for prosthetic limbs, and he has collaborations with the Center for Bionic Medicine at the Shirley Ryan AbilityLab, the John Rogers Research Group at Northwestern University, and the Range of Motion Project in Guatemala and Ecuador. In 2021, he was named as one of MIT Technology Review’s top 35 Innovators Under 35 and America’s Top 50 Disruptors in Newsweek.

Chris Baschuk

Chris Baschuk, MPO, CPO, LP, FAAOP(D) is an Upper Limb Prosthetics Specialist having lectured nationally and internationally extensively on the topic of upper limb prosthetic rehabilitation. He is the Director of Clinical Services for Point Designs, LLC. He currently serves as the Chair of the Upper Limb Prosthetics Society of the American Academy of Orthotists and Prosthetists. Chris is a graduate of the University of Utah with a BS in Biomedical Engineering and obtained his Masters of Prosthetics and Orthotics at UT Southwestern Medical Center. He lives in Centerville, UT with his wife and four children.

Samer Moussa

Samer Moussa has a background that merges design, clinical care, and business development of medical devices. With an undergrad in Mechanical Engineering, a Masters of Science in Orthotics and Prosthetics and an MBA from Boston University, he has transitioned from everyday clinical care as a CPO to working in product management with different medical device manufacturers. From adjustable prosthetic sockets with LIM Innovations to innovative off-the-shelf knee and spine devices with Breg and the latest venture with HP, Arize Orthotics which is a fully developed end-to-end solution for custom orthotics. Samer has been in the O&P industry for over 10 years and his main passion is finding the right bridge between new technology and clinical pain points in a way that both businesses can strive.

Jackie Bailey

Jackie works at EastPoint as Clinical Director and ABC Certified Prosthetist. Jackie is a native of Ohio, and received her Bachelor’s degree in Exercise Science and Sports Management from Mount Vernon Nazarene University. She then went on to Northwestern University to obtain her certification in Prosthetics. She works closely with rehab teams in hospital and skilled nursing settings to increase successful prosthetic use in amputee patients. Jackie is passionate about providing a high level of patient care, and giving every amputee a chance to thrive.

Moderator:

W. Brent Wright

W. Brent Wright, CP, BOCO, practices at Eastpoint Prosthetics and Orthotics in Raleigh, NC. He has been in the field since he started as a technician at age 16 and has seen firsthand how additive technology is evolving and impacts patients not only in the US but also in the developing world. He graduated from Appalachian State University with a BS in Healthcare Management and continued with a post baccalaureate certificate from California State University for Prosthetics. Brent is pioneering techniques to effectively use additive technology such as MultiJet Fusion and Selective Laser Sintering to create dynamic prostheses that are light as well as flexible. He is excited that prosthetists have a chance to be a part of the industrial revolution where mass customization and patient outcomes collide. Brent is the Clinical Director of LifeNabled, a non-profit that specializes in manufacturing all new low-cost and high-quality prostheses. LifeNabled has developed a scanning app for the iPad and iPhone called Digiscan3D and also has developed a suitcase 3D printer that can be deployed anywhere in the world. He sees a world where all amputees have access to prostheses because of scanning and 3D printing.

3D bioprinting is a relatively new technology that has the potential to revolutionize drug discovery and development. Here are some ways 3D bioprinting can help in this field: 1) Generating realistic in vitro models: 3D bioprinting can create three-dimensional tissue structures that closely mimic the in vivo environment. These structures can be used to test the efficacy and toxicity of drugs in a more realistic setting than traditional two-dimensional cell culture methods. This can help researchers identify promising drug candidates earlier in the drug development process, which can save time and resources. 2) Personalized medicine: 3D bioprinting can be used to create patient-specific tissues or organs for drug testing. This can help identify drugs that are effective for a particular patient population, as well as identify potential adverse effects that may not be detected in traditional preclinical testing. 3) High-throughput screening: 3D bioprinting can enable the creation of large numbers of complex tissue models in a relatively short amount of time. This can allow for high-throughput screening of potential drug candidates, which can speed up the drug discovery process and reduce costs. 4) Target identification: 3D bioprinting can help researchers identify new drug targets by enabling the creation of more complex tissue structures that better mimic the in vivo environment. This can provide researchers with a more complete understanding of disease biology and help identify new therapeutic targets. 5) Overall, 3D bioprinting has the potential to improve the drug discovery and development process by enabling the creation of more realistic in vitro models, accelerating the drug discovery process, and improving patient outcomes through personalized medicine. In this highly anticipated event, we invite critical stakeholders in the 3D bioprinting drug development ecosystem to update the community on where we are in terms of technologies and commercialization of the technologies.

Speakers:

Andrew Lee

Andrew Lee is a co-founder at FluidForm, a 3D biofabrication company looking to change the way we think about tissue engineering and regenerative medicine. He currently is the Product Manager for the Cardiac Group at FluidForm. He received his Ph.D. in Biomedical Engineering at Carnegie Mellon University where his focus on muscle tissue engineering leveraged biofabrication to create skeletal and cardiac tissue models with complex tissues architecture as well as physiologically relevant contractile functions. This work resulted in a publication in the journal Science and is now utilized as the platform technology for FluidForm as it builds out a portfolio of tissues for research, repair, and replacement.

Kevin Vos

Kevin is the Director of Preclinical R&D at VoxCell BioInnovation. He acquired his Bachelor’s of Science from the University of Victoria in Biochemistry. He then completed his Ph. D. also from the University of Victoria in physical chemistry studying the photo-physical characterization of supramolecular complexes. After his Ph.D., Kevin completed a post-doctoral fellowship at the University of Calgary working with the World Health Organization studying the decontamination and reuse of PPE during the SARS-CoV-2 pandemic. Kevin then joined VoxCell in December 2021, as a tissue engineering scientist where he now leads the development of VoxCell’s tissue models.

Orquidea (Orchid) Garcia, PhD, MS

As a Johnson & Johnson Fellow and Lead for 3D Bioprinting and Tissue Regen Technologies, Orquidea (Orchid) Garcia is the technical lead for 3D bioprinting, and related tissue regen technology development. She is responsible for evaluation and execution of technical strategies and new technology integration to develop a new class of next-generation healthcare solutions. Orchid works closely with internal business partners, as well as technology, academia and government partners to develop J&J’s bioprinting capabilities.    

Orchid has extensive experience identifying novel technologies through scientific discovery and translating them into patentable, marketable technologies both in industry and academia. Having served as the scientific subject matter expert on numerous initiatives, she brings a keen understanding of world-wide technical, scientific, regulatory and policy issues that face the business. Orchid has also held various positions within J&J and in industry in Clinical Affairs, Medical Affairs and Regulatory Affairs. 

Isabella Bondesson

Isabella Bondesson is a Field Application Scientist at CELLINK, the global leading bioprinting company. Isabella has a BioTech Engineering degree from Chalmers Institute of Technology, and she joined CELLINK in 2018 as part of the R&D team to develop novel methods in tissue model printing. During her time at CELLINK Isabella has acquired expertise in multiple areas of bioprinting and is today leading the EMEA Application team who work with consulting, educating, and supporting customer needs within various aspect of 3D Bioprinting. As the leading 3D bioprinting company, CELLINK is committed to providing the most advanced 3D bioprinting products, services and technologies needed to understand and master biology. CELLINK develops technologies that democratize 3D bioprinting – providing the leading researchers in the world the tools they need to create the future of health.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

3D printing and bioprinting to regenerate bone both are promising for the regeneration of bone tissue. It uses 3D printing to create acellular scaffolds or 3D bioprinting bio-inks that contain living cells and growth factors to promote bone growth. This technology has the potential to create exact replicas of damaged bone, which could then be implanted in the body to help regenerate lost tissue. The process begins with scanning the bone defect to create a 3D model of the desired bone structure. Then, biomaterials or bio-ink containing stem cells and growth factors are printed in the desired structure based on the 3D models. The scaffold acts as a supportive structure for the cells, which are then allowed to grow in the desired shape. Once the cells have grown and matured, they can then be implanted into the patient’s body. This technology has been successfully used to regenerate bone in animals and is now being tested in human clinical trials. Some of the forerunners in the field include Osteopore (Singapore), Ossiform(Denmark, previously known as Particle 3D), DimensionInx(U.S., Chicago), and Cerhum(Belgium). In this upcoming virtual event, we invite all stakeholders with different backgrounds to learn and participate focusing on how we can use 3D printing to regenerate bone tissues.

Speakers:

Raphael Lichtnecker

I got my Master´s degree in Pharmaceutical Bioprocess Engineering at Technical University Munich. Afterwards I started as Business Development Manager at ViscoTec where I am responsible for the technology transfer of the progressive cavity pump to the bioprinting sector. I´m in this position for almost five years now.

Elisabeth Cobraiville

Elisabeth is a biomedical engineer specialized in biomaterials. She also holds a university certificate in Quality, Regulatory and Clinical Affairs of medical devices. Prior to joining CERHUM, she worked in a CRO and managed preclinical and clinical trials. She joined CERHUM almost 4 years ago and she is in charge of the products technical file, animal studies and clinical trials.

Daniel Kelly

Prof Daniel Kelly leads a multidisciplinary musculoskeletal tissue engineering group based in the Trinity Centre for Biomedical Engineering. The goal of his lab is to understand how environmental factors regulate the fate of adult progenitor cells and the tissues they produce. This research underpins a more translational programme aimed at developing novel tissue engineering and 3D bioprinting strategies to regenerate damaged and diseased musculoskeletal tissues. To date he has published over 200 articles in peer-reviewed journals. He is the recipient of four European Research Council awards (Starter grant 2010; Consolidator grant 2015; Proof of Concept grant 2017; Advanced grant 2021).

Denys Gurak

Denys Gurak is an experienced C-level manager and serial entrepreneur. He is a CEO and Co-Founder at A.D.A.M., a 3D bioprinting company with a primary focus on 3D-printed bones. Denys’s ultimate vision is to build an on-demand personalized tissue manufacturing platform that would be a one-stop shop for transplanted tissues and organs; and, hence, to cut barriers to medical treatment for millions. Denys’s passion for biotech can be traced back to 2010, when he was leading the international relations and certification, along with EU legislation adaptation at the Ukrainian medicinal products regulatory authority (official position – director of the «GMP/GDP Center» of the State Administration of Ukraine on Medicinal Products (SAUMP). In 2014 Denys joined the Ukrainian Defense Industry (a state defense conglomerate) in 2014 as the Deputy Director-General for foreign economic activity. During his time at the company, he managed the export-import operations that amounted to USD 1 billion yearly turnover. Furthermore, Denys represented Ukraine as the Head of Ukraine’s delegation to the NATO Industrial Advisory Group (NIAG), and led the industry transformation initiatives, including innovations development and technology JVs, as well international relations. Denys is a Venture Partner at ff Venture Capital a high-performing early stage venture firm based in NYC and Warsaw, Poland, focusing on disruptive IT, biotechnology, aerospace and security projects in CEE region.

Dan Rogozea

Dan Rogozea started working in the bioprinting field with the mission to produce the smallest bones in the human body, the ossicles. This project started in 2018 and initiated his work in the bioprinting field. In collaboration with Dr. Moldovan at the Roudebush VA Medical Center Bioprinting Core, he has continued to work in multiple projects in different fields ranging from cardiovascular to dental bioprinting projects. As an expert in the field Dan Rogozea continues to work in research and for well -known bioprinting companies.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.